Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)

Inclusion Criteria: * Participant must be at least 18 years of age inclusive, at the time of signing the informed consent. * Documented history of physician diagnosed moderate or severe asthma for \>=12 months based on Guidelines and treated with inhaled corticosteroid (ICS) and long-acting beta-2-agonist (LABA) for at least 4 months (\>=500 micrograms/day \[µg/day\]) fluticasone propionate or equivalent as defined in the guidelines. * Pre-bronchodilator FEV1 35-79% of predicted value for participant inclusive * FeNO \>= 25 parts per billion (ppb) at Screening * ACQ-5 score \>= 1.5 at Screening * Blood eosinophil \>=300 cells/microliter at Screening * Evidence of allergic fungal airway disease like Fungal sensitization to any of the fungi Aspergillus fumigatus, Penicillium chrysogenum (notatum) at screening measured by serum-specific Immunoglobulin (Ig) E test. A history of exacerbations with at least 1 severe exacerbation (defined as requiring a minimum of 3 days of high-dose oral corticosteroids for asthma symptoms) in the previous 12 months. * Body weight within 50-150 kilogram (kg) * Both male and female gender. A female participant is eligible to participate if she is not pregnant not breastfeeding, Not a woman of childbearing potential (WOCBP) or A WOCBP who agrees to follow the contraceptive guidance during the treatment period and for at least 16 weeks after the last dose of study treatment. * Capable of giving signed informed consent Exclusion Criteria: * Historic…